GSK 2586881

Drug Profile

GSK 2586881

Alternative Names: 2586881; APN-01; GSK2586881; Recombinant-human-soluble-angiotensin-converting-enzyme-2-Apeiron-Biologics; rhACE2; rhACE2-Apeiron-Biologics

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; GlaxoSmithKline
  • Class Antihypertensives; Antineoplastics; Recombinant proteins
  • Mechanism of Action ACE stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Pulmonary arterial hypertension
  • Discontinued Cancer; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 24 May 2017 Phase-II clinical trials in Pulmonary arterial hypertension in Spain (IV) (EudraCT2017-000212-41)
  • 23 May 2017 GlaxoSmithKline plans a phase II trial for Pulmonary arterial hypertension in USA (IV, Infusion) (NCT03177603)
  • 17 May 2017 Phase-I clinical trials in Adult respiratory distress syndrome (In volunteers) in Germany (IV) (NCT03000686)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top